Awards and Accomplishments
About Dr. Heinzerling
Dr. Keith Heinzerling practices internal medicine and is an addiction medicine specialist at the Pacific Brain Health Center, Pacific Neuroscience Institute. His clinical and research focuses are on the treatment of alcohol, drug and substance use problems, with anti-addiction medications. As director of the Treatment & Research In Psychedelics (TRIP) program, he is involved in the development of psychedelic-assisted therapies for those suffering with addiction, depression, anxiety, and PTSD. He is the principal investigator of clinical trials using psilocybin-assisted therapy tackling conditions including alcohol use disorder and major depression. Dr. Heinzerling is a trained psychedelic guide and holds a Certificate in Psychedelic-Assisted Therapies and Research (CPTR) from the California Institute of Integral Studies (CIIS).
Dr. Heinzerling is a nationally recognized expert in Addiction Medicine with numerous research papers, presentations, and trainees to his credit. Working on new treatments and innovations that give patients hope that they can get better is what he loves most about practicing medicine.
Prior to joining PNI, Dr. Heinzerling was is an Associate Professor in the UCLA Department of Family Medicine. He was a founding member of the UCLA Comprehensive Chronic Pain Integrated Practice Unit and is founder of BDH Pharmaceuticals, LLC.
From an early age, inspired by his researcher mother, he wanted to be a scientist, but going into medicine fulfilled his desire to witness and impact science beyond the lab while improving peoples’ lives. He graduated from Stanford University School of Medicine and the Internal Medicine/Primary Care program at NYU/Bellevue Hospital where he was a Chief Resident.
He is the recipient of numerous awards and honors throughout his academic years and for his research. He is recognized as a “Top Doctor – Best Addiction Medicine” by Los Angeles Magazine. Dr. Heinzerling received a financial award to support a substance abuse start-up and treats patients for a variety of addictions including problems with opioids (heroin, prescription pain medications, and patients with addiction and chronic pain), alcohol, marijuana, methamphetamine, and cocaine.
He is active in community service, volunteering over the years in the New York and Los Angeles areas working with organizations by consulting and educating communities about addiction, prevention, and safety.
When not at work, Dr. Heinzerling enjoys running in the Santa Monica Mountains, hiking, skiing and backpacking.
Now accepting online and in-person appointments
Our specialists have consultation openings for new patients in crisis anywhere in California.
Schedule a virtual video or in-person visit by calling 310-582-7612.
For more information about the Treatment & Research in Psychedelics (TRIP) clinical trials program call 310-582-7611.
- Addiction Recovery
- Alcohol, Drug & Substance Abuse
- Psychedelic-Assisted Therapies
Medicare, medicaid and most insurance plans are accepted. Please contact us to confirm coverage.
- Addiction Disorders
- Treatment & Research In Psychedelics (TRIP) program
- Pacific Brain Health Center
- Schedule a Consultation
- Dr. Heinzerling’s CV
Clinic Location & Contact Information
Frequently Asked Questions
Yes, he is accepting new patients at this time.
Dr. Heinzerling’s clinical focus is addiction recovery.
Dr. Heinzerling speaks English.
Yes, Dr. Heinzerling is taking telehealth appointments. Please call 310-582-7612 to find out more about making an appointment.
Dr. Heinzerling’s office is located at 1301, 20th St, #540, Santa Monica CA 90404.
Videos by Dr. Heinzerling
Articles by Dr. Heinzerling
Managing Stress, Isolation, and Risk of Drug or Alcohol Relapse During the COVID-19 Pandemic
The affects of social distancing are a serious concern. Those who suffer from drug or alcohol problems are not only at risk of exposure, but may also be at risk of a relapse. How can stress and isolation during COVID-19 result in a relapse? The…
What is Ketamine Therapy?
Ketamine is approved for use at high doses as an anesthetic in the operating room. Although not FDA-approved, lower dose “sub-anesthetic” ketamine injections are used “off-label” to treat depression, pain, and other mental health/substance use disorders. In recent times, there have been many factors contributing…
Medical DegreeStanford University School of Medicine, Stanford, California
ResidencyInternship: Internal Medicine, NYU Medical Center/Bellevue Hospital, NY
Residency – Chief Resident: Internal Medicine, NYU Medical Center/Bellevue Hospital, NY
FellowshipRobert Wood Johnson Clinical Scholars Program, UCLA-VAMC
CertificationsAmerican Board of Internal Medicine, Diplomate
American Board of Addiction Medicine, Diplomate
American Society of Addiction Medicine, Addiction Medicine Certification
American Board of Addiction Medicine (Preventive Medicine), Diplomate